ライフサイエンスコーパス: adrenergic antagonist

1 was blocked by atenolol, a selective beta(1)-adrenergic antagonist.

2 tion of a beta(2) (but not beta(1) or alpha) adrenergic antagonist.

3 also delayed by treating mice with an alpha-adrenergic antagonist.

4 duced by therapy with phentolamine, an alpha-adrenergic antagonist.

5 Prazosin is a centrally active alpha(1) adrenergic antagonist.

6 fect was canceled by prior injection of beta-adrenergic antagonists.

7 otine was blocked by prior injection of beta-adrenergic antagonists.

8 tion was further indicated by the effects of adrenergic antagonists.

9 gical differences between these two alpha(2)-adrenergic antagonists.

10 adrenergic antagonist), or zinterol (a beta2-adrenergic antagonist) administered bilaterally into the

11 ntagonist, and yohimbine, a selective alpha2-adrenergic antagonist, also reduced L-NAME-induced const

12 trials in which the combination of an alpha1-adrenergic antagonist and ARI was used to treat symptoma

13 Freshly isolated strips were exposed to beta-adrenergic antagonists and agonists and assayed for cAMP

14 crements are reversed by propranolol, a beta-adrenergic antagonist, and abolished by selective bilate

15 combination of prazosin, a selective alpha1-adrenergic antagonist, and yohimbine, a selective alpha2

16 The selective beta 1-adrenergic antagonist atenolol (10(-6) M) did not affect

17 l) of either propranolol (a nonspecific beta-adrenergic antagonist), atenolol (a beta1-adrenergic ant

18 of a single injection of the specific alpha2-adrenergic antagonist atipamezole (1.5 mg/kg i.p.) after

19 Consistent with these findings, beta-adrenergic antagonists blocked both the late and the ear

20 ption partially blocked by intrathecal alpha-adrenergic antagonists, but the mechanism underlying thi

21 We also found that an alpha-adrenergic antagonist can specifically block the QseC re

22 ne epinephrine and show that beta- and alpha-adrenergic antagonists can block the bacterial response

23 Beta-adrenergic antagonists completely blocked the release of

24 Preinjection of yohimbine, an alpha 2-adrenergic antagonist, completely inhibited this increas

25 Yohimbine, a specific alpha2-adrenergic antagonist, completely prevented the inductio

26 was administered with and without the alpha-adrenergic antagonist dapiprazole, and its effects were

27 Doxazosin (50 nmol), an alpha(1)-adrenergic antagonist, decreased intercontraction interv

28 Propranolol, a generic beta-adrenergic antagonist, decreased proliferation of KS-ass

29 receptor antagonist) or propranolol (a beta-adrenergic antagonist) did not alter DA-stimulated clear

30 atic hyperplasia can be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth

31 energic agonist, phenylephrine, and a beta-1 adrenergic antagonist, esmolol, in 14 patients with POTS

32 The use of alpha-adrenergic antagonist for the treatment of pediatric uro

33 Atipamezole, a selective alpha-2 adrenergic antagonist, given into the LC, 10 microgram/L

34 his effect was blocked by use of the beta(2)-adrenergic antagonist ICI 118,551 but not by the alpha-a

35 renol was inhibited completely by the beta 2-adrenergic antagonist ICI-118,551 at 100 nM, with a half

36 ate the physician regarding the use of alpha-adrenergic antagonists in the management of various pedi

37 The affinities of various adrenergic antagonists in these ocular tissues were comp

38 ystemic co-administration of alpha- and beta-adrenergic antagonists in young (n = 9; 26 +/- 1 years o

39 in-deficient and wild-type mice while a beta-adrenergic antagonist increases bone mass in wild-type a

40 ompletely blocked by prior injection of beta-adrenergic antagonists, indicating that beta-adrenergic

41 Infusions of these beta-adrenergic antagonists into the central nucleus of the a

42 ions in vivo, we show that infusion of alpha-adrenergic antagonists into the NIf (nucleus interfacial

43 icial heart failure treatments, such as beta-adrenergic antagonists, involve improved contractility.

44 mprovements in symptoms compared with alpha1-adrenergic antagonist monotherapy after as little as 9 m

45 e evident after 1 year when comparing alpha1-adrenergic antagonist monotherapy and combination medica

46 ean decreases between those receiving alpha1-adrenergic antagonist monotherapy and combination medica

47 therapy demonstrated superiority over alpha1-adrenergic antagonist monotherapy.

48 ce was blocked by pretreatment with the beta-adrenergic antagonist, nadolol (0.5 mg/kg), but not by t

49 adrenergic antagonist, prazosin, an alpha 1-adrenergic antagonist, nor yohimbine, an alpha 2-specifi

50 tic benign prostatic hyperplasia over alpha1-adrenergic antagonist or ARI monotherapy, when prescribe

51 Nonselective alpha- and beta-adrenergic antagonists or saline were infused in the OB

52 Treatment with beta-adrenergic antagonists or with S107, a small molecule dr

53 ta-adrenergic antagonist), atenolol (a beta1-adrenergic antagonist), or zinterol (a beta2-adrenergic

54 Presurgical treatment with the alpha-adrenergic antagonist phentolamine completely prevented

55 e, and this increase is blocked by the alpha-adrenergic antagonist phentolamine.

56 h the nonselective alpha-adrenergic and beta-adrenergic antagonists phentolamine and propranolol, or

57 The application of alpha-adrenergic antagonists (phentolamine or phenoxybenzamine

58 tained presence in the culture of the alpha1-adrenergic antagonist prazosin (Pz) at 10(-7) M.

59 timulation by norepinephrine and an alpha(1)-adrenergic antagonist prazosin is not restored by pertus

60 [Ca2+]i signaling was blocked by the alpha1-adrenergic antagonist prazosin, whereas signaling in the

61 ked by pretreatment of cells with the alpha1-adrenergic antagonist prazosin.

62 opranolol but was not affected by the alpha1-adrenergic antagonist prazosin.

63 ptors since they were blocked by the alpha 1-adrenergic antagonist prazosin.

64 9)-10(-6) m), in the presence of an alpha(1)-adrenergic antagonist, prazosin (10(-6) m), selectively

65 Neither atenolol, a beta 1-specific adrenergic antagonist, prazosin, an alpha 1-adrenergic a

66 renaline release) and phentolamine (an alpha-adrenergic antagonist), profound vasodilatation was seen

67 Although the beta-adrenergic antagonist propranolol (1) binds at rodent 5-

68 Administration of the beta-adrenergic antagonist propranolol at encoding abolishes

69 is effect was completely blocked by the beta-adrenergic antagonist propranolol but was not affected b

70 When the beta-adrenergic antagonist propranolol was added to the stimu

71 (saline, 1, 3, 5 or 10 mg kg(-1) of the beta-adrenergic antagonist propranolol) were trained with a t

72 s (saline, 1, 3, 5 or 10 mg kg-1 of the beta-adrenergic antagonist propranolol) were trained with a t

73 n the NPE but not PE was blocked by the beta-adrenergic antagonist propranolol, the gap junction bloc

74 and these increases were blocked by the beta-adrenergic antagonist propranolol.

75 Moreover, a single injection of the beta-adrenergic antagonist, propranolol, prevented the noctur

76 er, incubation of RG20 cells with the alpha2-adrenergic antagonist rauwolscine or with pertussis toxi

77 Pretreatment with selective beta1- and beta2-adrenergic antagonists reduced the increase in phosphory

78 Alpha1-adrenergic antagonists relieve lower urinary tract sympt

79 of mice housed at 22 degrees C with a beta2-adrenergic antagonist reverses the norepinephrine-driven

80 The alpha2-adrenergic antagonist RX821002 abrogated this effect.

81 The beta-adrenergic antagonist sotalol (10-4 M) reduced LL absorp

82 ugh it is the most important target for beta-adrenergic antagonists, such as beta-blockers, relativel

83 usion of dobutamine or treatment with a beta-adrenergic antagonist, suggesting that RLC is constituti

84 ned the effects of administering an alpha-1A-adrenergic antagonist, Tamsulosin, on urodynamics.

85 tenuated by infusion of the selective alpha1 adrenergic antagonist terazosin into the basal forebrain

86 The hypotensive adrenergic antagonist timolol, propranolol, and betaxolo

87 The beta-adrenergic antagonists timolol and propranolol did not s

88 t to the microvessel preparation or an alpha-adrenergic antagonist to the myocytes and was augmented

89 ffect could be reversed by propranolol (beta-adrenergic antagonist) treatment.

90 ved vasoconstriction, phentolamine, an alpha-adrenergic antagonist was administered prior to MA treat

91 Furthermore, we found adrenergic antagonists were able to slow the rate of the

92 l melatonin formation and is induced by beta-adrenergic antagonists, which block melatonin production

93 in the heart and is the main target for beta-adrenergic antagonists, widely used in the treatment of

94 Compared with placebo, alpha-adrenergic antagonists will also aid significantly in th

95 OPC-28326 is a selective alpha-adrenergic antagonist with preferential binding to the a

96 nd this suppression was reversed by alpha(2)-adrenergic antagonists with an order of inverse efficacy

97 gn, we orally administered either the alpha2-adrenergic antagonist yohimbine (increasing noradrenergi

98 ic, that of Dex being blocked by the alpha-2 adrenergic antagonist yohimbine, 5 mg/kg, i.p.; that of

99 Pretreatment with the alpha 2-adrenergic antagonist, yohimbine (8 micrograms, I.C.V.),

100 of NE by approximately 30%, whereas alpha(2)-adrenergic antagonist, yohimbine, did not prevent the st